Vidac Pharma secures approval for next phase of clinical study of lead asset in Cutaneous T-Cell Lymphoma
12 mars 2024 02h30 HE
|
Vidac Pharma Holding PLC
London (UK), March 12, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a...
Vidac Pharma annonce des données positives de l'analyse intermédiaire de phase 2a pour son produit phare VDA-1102 dans le traitement des Lymphomes T cutanés (LCT), une maladie rare.
29 janv. 2024 02h00 HE
|
Vidac Pharma Holding PLC
London (UK), January 29, 2024 - Vidac Pharma Holdings Plc. (Hambourg et Stuttgart : T9G ; ISIN:GB00BM9XQ619 ; WKN : A3DTUQ), société biopharmaceutique d'oncologie de stade clinique, pionnière d'une...
Vidac Pharma reports positive interim Phase 2a data in orphan disease cutaneous T-cell lymphoma (CTCL) with lead asset VDA-1102
29 janv. 2024 02h00 HE
|
Vidac Pharma Holding PLC
London (UK), January 29, 2024 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a groundbreaking...
Photopheresis Products Market to exceed USD 488 billion by 2032, says Global Market Insights Inc.
27 juin 2023 07h00 HE
|
Global Market Insights Inc.
Selbyville, Delaware, June 27, 2023 (GLOBE NEWSWIRE) -- Photopheresis Products Market size is predicted to surpass USD 488 billion by 2032. Advancements in medical technology and increasing demand...
Global Cutaneous T-cell Lymphoma (CTCL) Treatment Market to be Driven by Rising Prevalence of Lymphoma Cancer and Growing Advances in Cancer Treatment at a CAGR of ~5% over 2022-2030
15 juil. 2022 10h47 HE
|
Research Nester
New York, July 15, 2022 (GLOBE NEWSWIRE) -- The different types of cancer that arise in the immune cells, also known as lymphocytes, are commonly termed as lymphoma. It is estimated that in the...
North America Cutaneous T-Cell Lymphoma (CTCL) Therapeutics Market Size [2022-2028] | to Reach USD 587.4 Million, at a CAGR 13.6%
16 févr. 2022 05h48 HE
|
Fortune Business Insights
Pune, India, Feb. 16, 2022 (GLOBE NEWSWIRE) -- North America cutaneous T-cell lymphoma (CTCL) therapeutics market size is projected to hit an annual valuation of USD 587.4 million by 2028,...
Global T-cell Lymphoma Market to Surpass US$ 2,495.4 Million by 2028, Says Coherent Market Insights (CMI)
20 déc. 2021 09h00 HE
|
CMI
SEATTLE, Dec. 20, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global T-cell lymphoma market is estimated to be valued at US$ 1,627.1 million in 2021 and is expected to...
Global Cutaneous T-cell Lymphoma Market is projected to be worth USD 3531.5 Million by 2030 I SPER Market Research
30 nov. 2021 12h07 HE
|
SPER Market Research Pvt. Ltd.
New York, Nov. 30, 2021 (GLOBE NEWSWIRE) -- The global cutaneous T-cell Lymphoma market is expected to grow at a CAGR of 8.56% from 2020 to reach USD 3531.5 billion by 2030. The growth is primarily...
Promising Treatment for Cutaneous T-cell Lymphoma Enters Clinical Trials
03 août 2021 20h00 HE
|
DelveInsight Business Research LLP
Los Angeles, USA, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Promising Treatment for Cutaneous T-cell Lymphoma Enters Clinical Trials Around 25+ key companies are developing Cutaneous T-Cell Lymphoma...
Rhizen Pharmaceuticals S.A. receives FDA orphan-drug designation for Tenalisib (RP6530) for treatment of cutaneous T-cell lymphoma (CTCL)
09 avr. 2018 07h00 HE
|
Rhizen Pharmaceuticals SA
La Chaux-de-Fonds, Switzerland, April 09, 2018 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A., today announced that the U.S. Food and Drug Administration (FDA) has granted orphan-drug designation...